ClinicalTrials.gg
CompletedNCT01727726Updated Jun 8, 2018Results posted

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

A Phase 3 interventional study of Brexpiprazole and Seroquel XR in Depressive Disorder, Depression and Depressive Disorder, Major, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 76 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-06-08.

Primary conditionDepressive Disorder, MajorRegistry: Depressive DisorderReclassifiedWhy we changed it
Registry
Depressive Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Depressive Disorder, Major
Why
  1. The study's listed conditions name Depressive Disorder, Major, a narrower term within Depressive Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,182
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
Largest of 24
2,182 · median 189
Started
2012
with 1 other
Phase 3
16 of 24
none open now
Registered
7th of 24
by date
Lead sponsor
15 of 24
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one has the largest enrollment, is one of 2 that started in 2012, is one of 16 in phase 3, and was the 7th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To compare the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy to an assigned open label antidepressant therapy (ADT) in the proposed subject population with MDD.

Read the detailed description

This is a trial designed to assess the safety and efficacy of brexpiprazole (flexible dose) as adjunctive therapy to an assigned known anti-depressant in depressed subjects. The trial consists of a continuous 18-week double-blind treatment period with a 30-day follow-up. Subjects who complete all trial visits through the Week 18 visit may be offered entry into an optional open-label rollover trial.

03

Conditions studied

  • Depressive Disorder
  • Depression
  • Depressive Disorder, Major
  • Mood Disorders
  • Mental Disorders

Keywords

  • OPC-34712
  • brexpiprazole
  • Major Depressive Disorder
  • Adjunctive Treatment
04

In context

Depressive Disorder, Major Reclassified

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

This study's enrollment of 2,182 is above the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.

Browse Depressive Disorder, Major studies →

Lead sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.

Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.

Compared within Depressive Disorder, Major, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Depressive Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female outpatients 18 to 65 years of age, inclusive, at the time of .
  • Subjects with both a diagnosis of MDD, and in a current major depressive episode, as defined by criteria
  • Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.

Exclusion criteria

Exclusion Criteria:

  • Females who are breast-feeding and/or who have a positive pregnancy test result during screening prior to receiving trial medication
  • Subject has a current Axis I () diagnosis of: dementia, Schizophrenia, Bipolar, Eating disorder , Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder
  • Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the current major depressive episode.
  • Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days
  • Subjects currently treated with insulin for diabetes.
  • Subjects with uncontrolled hypertension
  • Subjects with known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass Surgery
  • Subjects with a positive drug screen for cocaine, marijuana, or other illicit drugs
  • Inability to swallow tablets or tolerate oral medication
  • Abnormal laboratory test results, vital signs and results
  • Subjects who previously participated in any prior brexpiprazole clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,182 participants (actual)

Study arms

  • Placebo comparator
    Placebo + ADT

    Matching Placebo and assigned ADT

    Drug: Placebo

  • Experimental
    Brexpiprazole + ADT

    Brexpiprazole, flexible dose and assigned ADT

    Drug: Brexpiprazole

  • Active comparator
    Seroquel XR + ADT

    Seroquel XR, flexible dose and assigned ADT

    Drug: Seroquel XR

Interventions

07

What researchers measure

Primary outcomes

  1. Montgomery Asberg Depression Rating Scale (MADRS)

    To determine the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy by assessment of MADRS total score. The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.

    Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).

Secondary outcomes

  1. Sheehan Disability Scale (SDS)

    To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale is a measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains ( work/social life/family life/home responsibilities). The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. Scores of 5 and above are associated with significant functional impairment. Additionally, SDS included 2 questions related to productivity losses due to the psychiatric symptoms and impairment.

    Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).

  2. Change From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.

    Change from end of Phase A in MADRS Total Score. The MADRS was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.

    Time frame: Change from baseline to week 2 and week 4 in Phase B (week 10/12 and week 12/14)

  3. Clinical Global Impression Score

    Mean change from end of Phase A in Clinical Global Impression - Severity of Illness scale (CGI-S) score and Improvement scale (CGI-I) during double-blind randomized Phase B treatment. CGI-S score assessed how mentally ill the patient was at that time. CGI-S score is calculated from 0 to 7 (0 indicates not assessed 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and7 indicated among the most extremely ill patient). CGI-I score is compared to his/her condition at baseline, how much has the patient changed. CGI-I score is calculated from 0 to 7 (0 indicates not assessed and 7 indicates very much worse).

    Time frame: From randomization to Phase B week 6 (14/16 weeks after randomization).

  4. MADRS Response at Week 6

    MADRS Response Rate, where response was defined as 50% reduction in MADRS Total Score, during double-blind randomized Phase B treatment.

    Time frame: Phase B week 6 (14/16 weeks after randomization).

  5. Number of Participants With MADRS

    MADRS Remission Rate, where remission was defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score, for every trial week visit during double-blind randomized Phase B treatment.

    Time frame: Phase B week 6 (14/16 weeks after randomization).

  6. CGI-I Response Rate

    CGI-I Response rate, where response was defined as a CGI-I score of 1 or 2 (very much improved or much improved), during double-blind randomized Phase B treatment.

    Time frame: Phase B week 6 (14/16 weeks after randomization).

  7. Number of Participants With Adverse Events

    To evaluate the safety and tolerability of brexpiprazole (flexible dose) as adjunctive therapy to ADT in the proposed subject population with MDD as AE variables.

    Time frame: From screening (Day -28 to Day-1) upto post treatment follow-up.

  8. Sheehan Disability Scale (SDS) Individual Item Scores.

    To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale (a self rated questionnaire) was used for measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains (work/school work, social life/leisure activities and family life/home responsibilities). All domains were rated on a score scale ranged from 0 (no impairment) to 10 (most severe). Score of 5 and above indicated significant functional impairment. A total score was addition of the 3 individual scores and the total score ranged from 0 (no impairment) to 30 (most severe).

    Time frame: Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).

08

Results

Posted Jun 8, 2018

Participant flow

Trial was conducted at 75 trial sites in 7 countries (United States, Russia, Poland, France, Serbia,Germany \& Canada). Phase A non-responders entered Phase B (503 subjects randomized in 2:2:1 (197+100+206) ratio - brexpiprazole/Seroquel extended release tablets/placebo +ADT).

Participant flow — Overall Study
MilestoneBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Started197100206
Completed17186186
Not completed261420

Outcome measures

PrimaryMontgomery Asberg Depression Rating Scale (MADRS)

To determine the efficacy of brexpiprazole (flexible dose) with placebo as adjunctive therapy by assessment of MADRS total score. The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.

Time frame:
Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Reported as:
Least squares mean · Units on a scale
Montgomery Asberg Depression Rating Scale (MADRS)
Units on a scaleBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Montgomery Asberg Depression Rating Scale (MADRS)-6.04 ± 0.43-4.86 ± 0.57-4.57 ± 0.41
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.0078 · Mean difference (final values): -1.48 · 95% CI -2.56 to -0.39Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.6642 · Mean difference (final values): -0.30 · 95% CI -1.63 to 1.04Mixed-model repeated measures (MMRM)
SecondarySheehan Disability Scale (SDS)

To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale is a measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains ( work/social life/family life/home responsibilities). The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. Scores of 5 and above are associated with significant functional impairment. Additionally, SDS included 2 questions related to productivity losses due to the psychiatric symptoms and impairment.

Time frame:
Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Reported as:
Least squares mean · units on a scale
Sheehan Disability Scale (SDS)
units on a scaleBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Sheehan Disability Scale (SDS)-0.97 ± 0.12-0.32 ± 0.16-0.74 ± 0.11
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.1334 · Mean difference (final values): -0.23 · 95% CI -0.52 to 0.07Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.0237 · Mean difference (final values): 0.42 · 95% CI 0.06 to 0.78Mixed-model repeated measures (MMRM)
SecondaryChange From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.

Change from end of Phase A in MADRS Total Score. The MADRS was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS depression rating scale was used to assess the subject's level of depression by utilizing the structured interview guide for the MADRS (SIGMA). The MADRS consisted of 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts), each rated 0 to 6. The overall score ranged from 0 (symptoms absent) to 60 (severe depression). Lower score indicated decreased severity of depression.

Time frame:
Change from baseline to week 2 and week 4 in Phase B (week 10/12 and week 12/14)
Reported as:
Least squares mean · units on a scale
Change From End of Phase A in MADRS Total Score for Trial Week 2 and Week 4.
units on a scaleBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Phase B Week 2-2.57 ± 0.32-2.26 ± 0.41-1.04 ± 0.31
Phase B Week 4-4.39 ± 0.39-3.30 ± 0.51-3.22 ± 0.37
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.0001 · Mean difference (final values): -1.53 · 95% CI -2.29 to -0.76Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.0103 · Mean difference (final values): -1.22 · 95% CI -2.15 to -0.29Mixed-model repeated measures (MMRM)
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.0185 · Mean difference (final values): -1.17 · 95% CI -2.15 to -0.20Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.8949 · Mean difference (final values): -0.08 · 95% CI -1.27 to 1.11Mixed-model repeated measures (MMRM)
SecondaryClinical Global Impression Score

Mean change from end of Phase A in Clinical Global Impression - Severity of Illness scale (CGI-S) score and Improvement scale (CGI-I) during double-blind randomized Phase B treatment. CGI-S score assessed how mentally ill the patient was at that time. CGI-S score is calculated from 0 to 7 (0 indicates not assessed 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and7 indicated among the most extremely ill patient). CGI-I score is compared to his/her condition at baseline, how much has the patient changed. CGI-I score is calculated from 0 to 7 (0 indicates not assessed and 7 indicates very much worse).

Time frame:
From randomization to Phase B week 6 (14/16 weeks after randomization).
Reported as:
Mean · Mean score
Clinical Global Impression Score
Mean scoreBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
CGI-Severity of Illness Scale3.98 ± 0.564.07 ± 0.584.02 ± 0.58
CGI-Improvement Scale Score2.55 ± 0.842.71 ± 0.872.74 ± 0.83
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.0350 · Mean difference (final values): -0.15 · 95% CI -0.29 to -0.01
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5601 · Mean difference (final values): -0.05 · 95% CI -0.22 to 0.12
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.0146 · Mean difference (final values): -0.19 · 95% CI -0.35 to -0.04
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.7127 · Mean difference (final values): -0.04 · 95% CI -0.23 to 0.15
SecondaryMADRS Response at Week 6

MADRS Response Rate, where response was defined as 50% reduction in MADRS Total Score, during double-blind randomized Phase B treatment.

Time frame:
Phase B week 6 (14/16 weeks after randomization).
Reported as:
Count of participants · Participants
MADRS Response at Week 6
ParticipantsBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
MADRS Response at Week 620814
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.2242 · Ratio of response rate: 1.49 · 95% CI 0.78 to 2.84
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.5998 · Ratio of response rate: 1.26 · 95% CI 0.53 to 2.98
SecondaryNumber of Participants With MADRS

MADRS Remission Rate, where remission was defined as MADRS Total Score ≤ 10 and 50% reduction in MADRS Total Score, for every trial week visit during double-blind randomized Phase B treatment.

Time frame:
Phase B week 6 (14/16 weeks after randomization).
Reported as:
Count of participants · Participants
Number of Participants With MADRS
ParticipantsBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Number of Participants With MADRS1329
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.3321 · Ratio of response rate: 1.52 · 95% CI 0.66 to 3.49
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.3917 · Ratio of response rate: 0.51 · 95% CI 0.11 to 2.46
SecondaryCGI-I Response Rate

CGI-I Response rate, where response was defined as a CGI-I score of 1 or 2 (very much improved or much improved), during double-blind randomized Phase B treatment.

Time frame:
Phase B week 6 (14/16 weeks after randomization).
Reported as:
Count of participants · Participants
CGI-I Response Rate
ParticipantsBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
CGI-I Response Rate1004879
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · Cochran-Mantel-Haenszel · p = 0.0032 · Ratio of response rate: 1.35 · 95% CI 1.10 to 1.66
  • Seroquel XR + ADT vs Placebo + ADT · Cochran-Mantel-Haenszel · p = 0.0898 · Ratio of response rate: 1.24 · 95% CI 0.98 to 1.59
SecondaryNumber of Participants With Adverse Events

To evaluate the safety and tolerability of brexpiprazole (flexible dose) as adjunctive therapy to ADT in the proposed subject population with MDD as AE variables.

Time frame:
From screening (Day -28 to Day-1) upto post treatment follow-up.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Death000
Serious TEAE011
Discontinuation due to TEAE241
Any TEAE10058107
SecondarySheehan Disability Scale (SDS) Individual Item Scores.

To evaluate mean change in SDS score from randomization (End of Phase A) to end of Phase B. The Sheehan Disability Scale (a self rated questionnaire) was used for measurement of functional disability and impairment due to psychiatric symptoms. The SDS is a visual analogue scale that uses spatio-visual, numeric, and verbal descriptive anchors simultaneously to assess disability across the three domains (work/school work, social life/leisure activities and family life/home responsibilities). All domains were rated on a score scale ranged from 0 (no impairment) to 10 (most severe). Score of 5 and above indicated significant functional impairment. A total score was addition of the 3 individual scores and the total score ranged from 0 (no impairment) to 30 (most severe).

Time frame:
Randomization Visit (week 8 or week 10) to End of Double-Blind Treatment (week 14 or week 16).
Reported as:
Least squares mean · units on a scale
Sheehan Disability Scale (SDS) Individual Item Scores.
units on a scaleBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
Work/School Score-0.59 ± 0.16-0.22 ± 0.21-0.74 ± 0.16
Social Life Score-1.03 ± 0.13-0.26 ± 0.17-0.70 ± 0.12
Family Life Score-1.02 ± 0.13-0.34 ± 0.18-0.67 ± 0.13
Statistical analysis
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.4480 · Mean difference (final values): 0.16 · 95% CI -0.25 to 0.56Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.0380 · Mean difference (final values): 0.52 · 95% CI 0.03 to 1.02Mixed-model repeated measures (MMRM)
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.0436 · Mean difference (final values): -0.34 · 95% CI -0.66 to -0.01Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.0350 · Mean difference (final values): 0.43 · 95% CI 0.03 to 0.84Mixed-model repeated measures (MMRM)
  • Brexpiprazole + ADT vs Seroquel XR + ADT · MMRM · p = 0.0424 · Mean difference (final values): -0.35 · 95% CI -0.69 to -0.01Mixed-model repeated measures (MMRM)
  • Seroquel XR + ADT vs Placebo + ADT · MMRM · p = 0.1230 · Mean difference (final values): 0.33 · 95% CI -0.09 to 0.75Mixed-model repeated measures (MMRM)

Adverse events

Collected over Adverse events were recorded from screening (Day -28 to Day-1) upto post treatment follow-up.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole + ADT0/197 (0%)0/197 (0%)62/197 (31.5%)
Seroquel XR + ADT0/100 (0%)1/100 (1%)33/100 (33%)
Placebo + ADT0/206 (0%)1/206 (0.5%)39/206 (18.9%)
Most frequent serious events
Most frequent serious events
EventBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
malignanat melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1971/1000/206
panic attackPsychiatric disorders0/1970/1001/206
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBrexpiprazole + ADTSeroquel XR + ADTPlacebo + ADT
SomnolenceNervous system disorders11/19718/1002/206
AkathisiaNervous system disorders12/1973/1004/206
HeadacheNervous system disorders11/1971/10010/206
Increased AppetiteMetabolism and nutrition disorders5/1975/1002/206
NasopharyngitisInfections and infestations9/1972/1009/206
fatigueGeneral disorders3/1974/1003/206
Weight IncreasedInvestigations7/1974/1004/206
DizzinessNervous system disorders7/1973/1005/206
InsomniaPsychiatric disorders5/1973/1004/206
RestlessnessPsychiatric disorders5/1971/1002/206

Baseline characteristics

Randomized sample comprised all subjects who were randomized in Phase B. Subjects were considered randomized when they were assigned a treatment number by IVRS at the end of Phase A. A subject receiving IMP outside of the IVRS was not considered randomized, but safety was reported.

Age, Categorical
Age, Categorical(Participants)Brexpiprazole + ADTSeroquel XR + ADTPlacebo + ADTTotal
<=18 years0000
Between 18 and 65 years197100206503
>=65 years0000
Age, Continuous
Age, Continuous(years)Brexpiprazole + ADTSeroquel XR + ADTPlacebo + ADTTotal
Mean43.6 ± 11.544.6 ± 11.641.8 ± 11.743 ± 11.7
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole + ADTSeroquel XR + ADTPlacebo + ADTTotal
Female12866149343
Male693457160
09

Study locations

76 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Bellflower, California, United States
  • Beverly Hills, California, United States
  • Costa Mesa, California 92626, United States
  • Glendale, California, United States
  • Irvine, California, United States
  • Redlands, California, United States
  • San Diego, California, United States
  • Upland, California, United States
  • Gainesville, Florida, United States
  • Jacksonville Beach, Florida, United States
  • Jacksonville, Florida, United States
  • Leesburg, Florida, United States
  • Melbourne, Florida, United States
  • Miami, Florida 33015, United States
  • Miami, Florida 33145, United States
  • Oakland Park, Florida, United States
  • Orange City, Florida, United States
  • Orlando, Florida, United States
  • Decatur, Georgia, United States
  • Lake Charles, Louisiana, United States
  • Baltimore, Maryland, United States
  • Belmont, Massachusetts, United States
  • Roslindale, Massachusetts, United States
  • Watertown, Massachusetts 02472, United States
  • Creve Coeur, Missouri, United States
  • Lebanon, New Hampshire, United States
  • New York, New York 10003, United States
  • New York, New York 10168, United States
  • Columbus, Ohio, United States
  • Dayton, Ohio, United States
  • Edmond, Oklahoma 73013, United States
  • Portland, Oregon, United States
  • Salem, Oregon, United States
  • Dallas, Texas, United States
  • Murray, Utah, United States
  • Herndon, Virginia, United States
  • Richmond, Virginia, United States
  • Bellevue, Washington, United States
  • Kirkland, Washington, United States
  • Seattle, Washington, United States
  • Brown Deer, Wisconsin, United States
  • Penticton, British Columbia, Canada
  • Dijon, France
  • Douai, France
  • Elancourt, France
  • Jarnac, France
  • Montepellier, France
  • Orvault, France
  • Achim, Germany
  • Mittweida, Germany
  • Stralsund, Germany
  • Wuerzburg, Germany
  • Belchatow, Poland
  • Bydgoszcz, Poland
  • Gdynia, Poland
  • Kielce, Poland
  • Lublin, Poland
  • Tuszyn, Poland
  • Wroclaw, Poland
  • Arkhangelsk, 163530, Russian Federation
  • Moscow, 107076, Russian Federation
  • Moscow, 127083, Russian Federation
  • Saint-Petersburg, 190020, Russian Federation
  • Saint-Petersburg, 191040, Russian Federation
  • Saint-Petersburg, 192019, Russian Federation
  • Saint-Petersburg, 199034, Russian Federation
  • Smolensk, Russian Federation
  • Tonnelniy, Russian Federation
  • Belgrade, 11000, Serbia
  • Belgrade, Serbia
  • Kragujevac, Serbia
  • Nis, Serbia
  • Novi Knezevac, Serbia
10

References and documents

Publications

  • Newcomer JW, Eriksson H, Zhang P, Meehan SR, Weiss C. Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies. J Clin Psychiatry. 2019 Oct 1;80(6):18m12680. doi: 10.4088/JCP.18m12680. PubMed 31577867 ↗
  • Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol. 2019 Mar 1;22(3):173-179. doi: 10.1093/ijnp/pyy095. PubMed 30508090 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Oct 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2012
First posted
Nov 16, 2012
Start
Dec 2012
Primary completionActual
Oct 17, 2016
CompletionActual
Nov 10, 2016
Results first posted
Jun 8, 2018
Last update
Jun 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01727726
Responsible party
Sponsor
First posted
Nov 16, 2012
Start date
Dec 2012
Primary completion
Oct 17, 2016
Completion
Nov 10, 2016
Results posted
Jun 8, 2018
Last update
Jun 8, 2018

Study contacts

Mary Hobart
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion